Artemin and immune checkpoint inhibitor (ICI) efficacy in metastatic colorectal cancer (mCRC): A correlative analysis of the Canadian Cancer Trials Group (CCTG) CO.26 trial

被引：0
|
作者：
Ma, Lucy Xiaolu
Titmuss, Emma
Jonker, Derek J.
Kennecke, Hagen Fritz
Berry, Scott R.
Couture, Felix
Ahmad, Chaudhary E.
Goffin, John R.
Kavan, Petr
Harb, Mohammed
Colwell, Bruce
Samimi, Setareh
Samson, Benoit
Abbas, Tahir
Aubin, Francine
Koski, Sheryl L.
Tu, Dongsheng
O'Callaghan, Christopher J.
Loree, Jonathan M.
Chen, Eric Xueyu
机构：
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Genome Sci Ctr, BCCA, Vancouver, BC, Canada
[3] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada
[4] Oregon Hlth & Sci Univ, Portland, OR USA
[5] Queens Univ, Kingston, ON, Canada
[6] Hotel Dieu Quebec, CHU Quebec, Quebec City, PQ, Canada
[7] Eastern Hlth, St John, NF, Canada
[8] Juravinski Canc Inst, Hamilton, ON, Canada
[9] Jewish Gen Hosp Sir Mortimer B Davis Jewish Gen H, Montreal, PQ, Canada
[10] Moncton City Hosp, Moncton, NB, Canada
[11] Nova Scotia Canc Care, Halifax, NS, Canada
[12] Hosp Sacr Coeur Montreal, Montreal, PQ, Canada
[13] Hop Charles LeMoyne, St Julie, PQ, Canada
[14] Saskatchewan Canc Agcy, Saskatoon, SK, Canada
[15] Ctr Hosp Univ Montreal, Montreal, PQ, Canada
[16] Cross Canc Inst, Edmonton, AB, Canada
[17] Queens Univ, Canadian Canc Trials Grp, Kingston, ON, Canada
[18] BC Canc Vancouver, Vancouver, BC, Canada
[19] Univ Hlth Network, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3587
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Optimal dosing of a novel PLK4 inhibitor nested in a phase II study of CFI-400945 in patients with Advanced/Metastatic Breast Cancer (MBC): Canadian Cancer Trials Group (CCTG) IND.237
    Rushton, M.
    Cescon, D.
    Hilton, J.
    Bedard, P.
    Blanchette, P.
    Bashir, A.
    Pezo, R.
    Kumar, V.
    Ng, T.
    Awan, A.
    Lott, A.
    Raphael, J. A.
    Hagerman, L.
    Bray, M.
    Muyot, L.
    Antras, J. Fuentes
    Seymour, L.
    Tu, D.
    Gaudreau, P. O.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S31 - S31
  • [42] Prognostic Significance of Neutrophil to Lymphocyte Ratio (NLR) in Relapsed/Refractory Aggressive Lymphoma Salvage Chemotherapy - Analysis of Canadian Cancer Trials Group (CCTG) ly.10 Trial
    Mohammadabadi, Mina Dehghani
    Hay, Annette E.
    Shepherd, Lois E.
    Crump, Michael
    Chen, Bingshu E.
    Baetz, Tara
    BLOOD, 2018, 132
  • [43] Proton Pump Inhibitor Use and the Efficacy of Chemotherapy in Metastatic Colorectal Cancer: A Post Hoc Analysis of a Randomized Phase III Trial (AXEPT)
    Kim, Sun Young
    Lee, Ji Sung
    Kang, Junho
    Morita, Satoshi
    Park, Young Suk
    Sakamoto, Junichi
    Muro, Kei
    Xu, Rui-Hua
    Kim, Tae Won
    ONCOLOGIST, 2021, 26 (06) : E954 - E962
  • [44] PD-L1 expression as a potential predictor of immune checkpoint inhibitor efficacy and survival in patients with recurrent or metastatic nasopharyngeal cancer: a systematic review and meta-analysis of prospective trials
    Xu, Ruyu
    Wong, Charlene H. L.
    Chan, Kenneth S. K.
    Chiang, Chi Leung
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [45] Beyond VEGF inhibition: Comparative efficacy analysis of novel VEGF and non-VEGF therapeutic agents in phase I trials for patients with metastatic colorectal cancer (mCRC).
    Patel, Sukeshi R.
    Ketchum, Norma
    Pollock, Brad H.
    Sarantopoulos, John
    Weitman, Steven
    Mahalingam, Devalingam
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [46] Systemic immune response invoked by short-course oxaliplatin-based chemotherapy (FLOX) for efficacy of sequential immune checkpoint blockade (ICB; nivolumab) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC)
    Meltzer, Sebastian
    Flatmark, Kjersti
    Fuglestad, Anniken J.
    Hamre, Hanne M.
    Kersten, Christian
    Hofsli, Eva
    Guren, Marianne G.
    Sorbye, Halfdan
    Negard, Anne
    Ree, Anne Hansen
    CANCER RESEARCH, 2023, 83 (07)
  • [47] Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer (mCRC): Final analysis-Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial
    Yuki, Satoshi
    Komatsu, Yoshito
    Fukushima, Hiraku
    Sasaki, Takahide
    Amano, Toraji
    Miyagishima, Takuto
    Hatanaka, Kazuteru
    Nakamura, Michio
    Tateyama, Miki
    Sakata, Yuh
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [48] Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer (mCRC): Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial-Comparison of the efficacy of KRAS status
    Nakamura, Michio
    Yuki, Satoshi
    Dazai, Masayoshi
    Kobayashi, Yoshimitsu
    Kato, Takashi
    Naruse, Hirohito
    Kudo, Mineo
    Akakura, Nobuaki
    Sakata, Yuh
    Komatsu, Yoshito
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [49] AMPHIREGULIN AND EPIREGULIN EXPRESSION PREDICTS FOR TREATMENT EFFICACY IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS TREATED WITH CETUXIMAB PLUS CAPIRI OR CAPOX. ANALYSIS OF THE GERMAN AIO CRC GROUP TRIAL: KRK-0204
    Stintzing, Sebastian
    Jung, Andreas
    Kapaun, Christine
    Reiche, Jana
    Modest, Dominik
    Giessen, Clemens
    Vehling-Kaiser, Ursula
    Stauch, Martina
    Hass, Holger
    von Weikersthal, Ludwig Fischer
    Kirchner, Thomas
    Heinemann, Volker
    ANNALS OF ONCOLOGY, 2011, 22 : v16 - v16
  • [50] Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials (vol 26, pg 5910, 2008)
    Arkenau
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) : 5859 - 5859
12345